Search

TG Therapeutics Inc

Затворен

СекторЗдравеопазване

48.74 2.01

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

47.16

Максимум

48.91

Ключови измерители

By Trading Economics

Приходи

7.8M

28M

Продажби

35M

240M

P/E

Средно за сектора

18.207

57.002

EPS

0.05

Марж на печалбата

11.466

Служители

399

EBITDA

-6.4M

22M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+35.88% upside

Дивиденти

By Acuity

Следващи печалби

2.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

458M

7.5B

Предишно отваряне

46.73

Предишно затваряне

48.74

Настроения в новините

By Acuity

6%

94%

7 / 340 Класиране в Healthcare

TG Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.08.2026 г., 21:01 ч. UTC

TG Therapeutics Inc shares are lower in after-market trading amid broader market weakness. Disappointing U.S. retail sales data may be impacting investor sentiment.

13.08.2026 г., 20:02 ч. UTC

Social Media

TG Therapeutics Inc shares declined during Thursday's session, influenced by social media sentiment and prior bearish commentary from Bank of America.

10.08.2026 г., 19:16 ч. UTC

TG Therapeutics Inc shares are lower today amid a broader market decline, with U.S. stock futures dropping following a surprising labor market report.

7.08.2026 г., 23:16 ч. UTC

TG Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement, which may reflect broader market sentiment.

6.08.2026 г., 20:03 ч. UTC

News

TG Therapeutics is lower today, impacted by declines in the Biotechnology sector. The company reported higher revenue but noted a decrease in net income and EPS.

5.08.2026 г., 19:56 ч. UTC

Social Media

TG Therapeutics is higher as analysts project GAAP net income could exceed $350 million in 2027, driven by revenue growth and pipeline developments.

4.08.2026 г., 23:56 ч. UTC

TG Therapeutics Inc. shares are roughly flat in after-market trading. The price remains below its 20-day moving average, indicating ongoing weakness.

3.08.2026 г., 23:06 ч. UTC

Social Media

TG Therapeutics Inc. shares are higher in after-market trading following Q2 revenues of $236 million and ongoing positive sentiment from clinical trials.

31.07.2026 г., 23:16 ч. UTC

No specific news was identified for TG Therapeutics Inc. After-market trading remains routine, with the stock showing little change in value.

30.07.2026 г., 23:56 ч. UTC

TG Therapeutics Inc shares are lower in after-market hours, with no specific news identified for the decline amid broader market uncertainty over interest rates.

29.07.2026 г., 15:52 ч. UTC

Social Media
News

TG Therapeutics shares are lower amid negative sentiment following the announcement of a conference call to discuss second quarter results and future outlook.

28.07.2026 г., 19:56 ч. UTC

TG Therapeutics shares are lower today amid broader market declines and a significant drop in the Nikkei 225 Index, reflecting negative sentiment.

27.07.2026 г., 19:07 ч. UTC

Social Media

B. Riley raised its price target for TG Therapeutics to $86, citing strong demand for Briumvi and anticipated revenue growth. Shares are trading roughly flat.

24.07.2026 г., 23:21 ч. UTC

TG Therapeutics Inc shares are lower in after-market hours, reaching a significant decline and hitting the lowest point of the day. No specific news was identified.

23.07.2026 г., 23:22 ч. UTC

TG Therapeutics traded roughly flat in after-market hours, with minimal change since Thursday's close, oscillating within its one-month trading range.

22.07.2026 г., 23:31 ч. UTC

TG Therapeutics Inc shares declined in after-market trading, reflecting a shift toward the lower end of its one-month trading range amid broader market pressures.

21.07.2026 г., 22:21 ч. UTC

TG Therapeutics shares are higher in after-market trading, tracking broader market gains following positive earnings from General Motors and 3M.

20.07.2026 г., 23:22 ч. UTC

TG Therapeutics shares are higher in after-market trading, recovering from a prior dip despite broader market pressures and four consecutive sessions of declines.

Сравнение с други в отрасъла

Ценова промяна

TG Therapeutics Inc Прогноза

Ценова цел

By TipRanks

35.88% нагоре

12-месечна прогноза

Среден 65.14 USD  35.88%

Висок 86 USD

Нисък 21 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за TG Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

5

Купи

1

Задържане

1

Продай

Настроение

By Acuity

7 / 340 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat